ACRS · Aclaris Therapeutics, Inc.
$5.17
-0.16 (-3.00%)
At close · Jul 29
Market Cap
$744.41M
Shares
139.66M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.83M
-58.2%
FY2025
Net Income
-$64.92M
+50.8%
FY2025
Gross Margin
52.69%
+24.4pp
FY2018
Operating Margin
-975.91%
-217.7pp
FY2025
Diluted EPS
-$0.53
+69%
FY2025
Operating Cash Flow
-$47.11M
-134.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8.37M | $7.83M | $18.72M | $31.25M | $29.75M | $6.76M | $6.48M | $4.23M | $6.15M | $1.68M | — | — | — | — | |
| $1.98M | $2.09M | $2.79M | $3.42M | $4.02M | $4.71M | $5.13M | $4.06M | $4.33M | $1.21M | — | — | — | — | |
| — | — | — | — | — | — | — | — | $3.24M | $476K | — | — | — | — | |
| — | — | — | — | — | — | — | — | 52.69% | 28.28% | — | — | — | — | |
| $56.72M | $52.65M | $33.59M | $98.38M | $77.81M | $43.81M | $29.34M | $64.17M | $60.84M | $35.8M | $33.48M | $15.34M | $6.51M | $3.49M | |
| — | — | — | — | — | — | — | $671K | $170K | $85K | $3.3M | — | — | — | |
| $22.58M | $21.97M | $22.2M | $32.41M | $25.13M | $23.62M | $20.53M | $27.83M | $25.76M | $18.95M | $11.8M | $5.33M | $2.03M | $1.77M | |
| — | — | — | $75K | $75K | $75K | $75K | $75K | $75K | $31K | $0 | — | — | — | |
| — | $454K | $807K | $863K | $797K | $923K | $1.32M | $6.41M | $1.88M | $402K | $120K | $90K | — | — | |
| — | — | — | $3.1M | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $138.66M | $72.9M | $48.57M | $20.67M | $8.53M | $5.26M | |
| $88.85M | $84.2M | $160.65M | $128.61M | $119.61M | $96.48M | $57.39M | $115.29M | $90.93M | $56.04M | — | — | — | — | |
| -$80.48M | -$76.38M | -$141.93M | -$97.36M | -$89.85M | -$89.72M | -$50.91M | -$111.06M | -$84.78M | -$54.36M | -$48.57M | -$20.67M | -$8.53M | -$5.26M | |
| — | -975.91% | -758.18% | -311.55% | -302.01% | -1327.07% | -785.44% | -2627.35% | -1378.31% | -3230.01% | — | — | — | — | |
| — | -$75.92M | -$141.13M | -$96.49M | -$89.06M | -$88.8M | -$49.59M | -$104.65M | -$82.9M | -$53.96M | -$48.45M | -$20.58M | — | — | |
| $6.99M | $7.64M | $7.95M | $8.51M | — | — | — | — | — | — | — | — | — | — | |
| $10.82M | $11.45M | $9.87M | $8.51M | $2.95M | -$1.14M | -$424K | -$2.48M | $2.68M | $2.07M | $488K | $104K | $16K | — | |
| — | -$64.92M | -$132.07M | -$88.85M | -$86.91M | -$90.87M | -$51.34M | -$113.54M | -$82.1M | -$70.35M | -$48.08M | -$20.56M | -$8.52M | — | |
| — | — | — | -$367K | — | — | -$182K | — | — | -$1.83M | — | — | — | — | |
| -$69.66M | -$64.92M | -$132.07M | -$88.48M | -$86.91M | -$90.87M | -$51.02M | -$161.35M | -$132.74M | -$68.52M | -$48.08M | -$20.56M | -$8.52M | -$5.24M | |
| — | -829.58% | -705.48% | -283.15% | -292.11% | -1343.96% | -787.03% | -3817.22% | -2157.99% | -4071.48% | — | — | — | — | |
| -$117.12M | — | — | — | — | — | — | — | — | -$68.52M | -$48.08M | -$23.13M | -$10.57M | -$6.98M | |
| -$70.07M | -$64.41M | -$131.86M | -$87.69M | -$87.58M | -$91M | -$51.04M | -$161.35M | -$132.56M | -$68.5M | -$48.2M | -$20.71M | -$8.53M | -$5.23M | |
| USD/shares | — | -$0.53 | -$1.71 | -$1.27 | -$1.33 | -$1.60 | -$1.20 | -$3.90 | — | — | — | — | — | — |
| USD/shares | — | -$0.53 | -$1.71 | -$1.27 | -$1.33 | -$1.60 | -$1.20 | -$3.90 | — | — | — | — | — | — |
| shares | — | 122.56M | 77.3M | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.1M | 21.42M | 6.11M | 1.72M | 1.08M |
| shares | — | 122.56M | 77.3M | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.1M | 21.42M | 6.11M | 1.72M | 1.08M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.65×
EV/EBIT
—
Peer median 24.71×
P/E (TTM)
—
Peer median 10.79×
Peer medians compare against the 301 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Single Reportable Segment | $7,826,000 | $18,720,000 | — | — | — | — | — | — |
| Contract Research Segment | — | — | $3,035,000 | $4,396,000 | $5,829,000 | $13,319,000 | $16,824,000 | $13,135,000 |
| Dermatology Therapeutics Segment | — | — | $28,214,000 | $25,356,000 | $932,000 | $696,000 | — | $1,500,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| License And Service | $5,954,000 | $16,179,000 | $28,214,000 | $25,100,000 | $809,000 | $690,000 | — | — |
| Laboratory Research Revenue | $1,872,000 | $2,541,000 | $3,035,000 | $4,395,000 | $5,830,000 | $5,786,000 | $4,227,000 | $4,651,000 |
| Other Revenue | — | — | — | $257,000 | $122,000 | $6,000 | — | $1,500,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Single Reportable Segment | -$76,375,000 | -$141,932,000 | — | — | — | — | — | — |
| Contract Research Segment | — | — | -$3,943,000 | -$2,347,000 | -$1,485,000 | -$1,703,000 | -$2,167,000 | -$445,000 |
| Dermatology Therapeutics Segment | — | — | -$65,563,000 | -$65,880,000 | -$67,666,000 | -$31,474,000 | -$84,422,000 | -$60,915,000 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Single Reportable Segment | -975.9% | -758.2% | — | — | — | — | — | — |
| Contract Research Segment | — | — | -129.9% | -53.4% | -25.5% | -12.8% | -12.9% | -3.4% |
| Dermatology Therapeutics Segment | — | — | -232.4% | -259.8% | -7260.3% | -4522.1% | — | -4061% |
Key facts
CIK
1557746
CUSIP
00461U105
13F (30d)
18 filings
18 filers
Visit website
Investor relations